Previous Close | 214.55 |
Open | 215.70 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's Range | 215.70 - 219.30 |
52 Week Range | 212.30 - 298.40 |
Volume | |
Avg. Volume | 931,695 |
Market Cap | 185.752B |
Beta (5Y Monthly) | 0.18 |
PE Ratio (TTM) | 16.84 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 9.50 (3.99%) |
Ex-Dividend Date | Mar 16, 2023 |
1y Target Est | N/A |
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Q1 2024 Sarepta Therapeutics Inc Earnings Call
Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.